QQQ   282.45 (-0.61%)
AAPL   115.85 (-0.87%)
MSFT   212.99 (-0.84%)
FB   276.73 (-0.72%)
GOOGL   1,590.21 (+0.27%)
AMZN   3,145.89 (-1.23%)
TSLA   429.87 (+1.71%)
NVDA   533.75 (-1.34%)
BABA   306.22 (-0.57%)
CGC   19.78 (+1.49%)
GE   7.59 (+3.69%)
MU   53.40 (+0.17%)
AMD   79.03 (-0.21%)
T   28.43 (+6.40%)
F   7.98 (+1.66%)
ACB   4.74 (-2.27%)
GILD   59.97 (-0.40%)
NFLX   484.00 (-1.03%)
BA   165.34 (+0.90%)
NIO   27.15 (-2.55%)
DIS   126.89 (+0.21%)
QQQ   282.45 (-0.61%)
AAPL   115.85 (-0.87%)
MSFT   212.99 (-0.84%)
FB   276.73 (-0.72%)
GOOGL   1,590.21 (+0.27%)
AMZN   3,145.89 (-1.23%)
TSLA   429.87 (+1.71%)
NVDA   533.75 (-1.34%)
BABA   306.22 (-0.57%)
CGC   19.78 (+1.49%)
GE   7.59 (+3.69%)
MU   53.40 (+0.17%)
AMD   79.03 (-0.21%)
T   28.43 (+6.40%)
F   7.98 (+1.66%)
ACB   4.74 (-2.27%)
GILD   59.97 (-0.40%)
NFLX   484.00 (-1.03%)
BA   165.34 (+0.90%)
NIO   27.15 (-2.55%)
DIS   126.89 (+0.21%)
QQQ   282.45 (-0.61%)
AAPL   115.85 (-0.87%)
MSFT   212.99 (-0.84%)
FB   276.73 (-0.72%)
GOOGL   1,590.21 (+0.27%)
AMZN   3,145.89 (-1.23%)
TSLA   429.87 (+1.71%)
NVDA   533.75 (-1.34%)
BABA   306.22 (-0.57%)
CGC   19.78 (+1.49%)
GE   7.59 (+3.69%)
MU   53.40 (+0.17%)
AMD   79.03 (-0.21%)
T   28.43 (+6.40%)
F   7.98 (+1.66%)
ACB   4.74 (-2.27%)
GILD   59.97 (-0.40%)
NFLX   484.00 (-1.03%)
BA   165.34 (+0.90%)
NIO   27.15 (-2.55%)
DIS   126.89 (+0.21%)
QQQ   282.45 (-0.61%)
AAPL   115.85 (-0.87%)
MSFT   212.99 (-0.84%)
FB   276.73 (-0.72%)
GOOGL   1,590.21 (+0.27%)
AMZN   3,145.89 (-1.23%)
TSLA   429.87 (+1.71%)
NVDA   533.75 (-1.34%)
BABA   306.22 (-0.57%)
CGC   19.78 (+1.49%)
GE   7.59 (+3.69%)
MU   53.40 (+0.17%)
AMD   79.03 (-0.21%)
T   28.43 (+6.40%)
F   7.98 (+1.66%)
ACB   4.74 (-2.27%)
GILD   59.97 (-0.40%)
NFLX   484.00 (-1.03%)
BA   165.34 (+0.90%)
NIO   27.15 (-2.55%)
DIS   126.89 (+0.21%)
Log in
NASDAQ:OPK

Opko Health Stock Forecast, Price & News

$4.25
+0.07 (+1.67 %)
(As of 10/22/2020 11:03 AM ET)
Add
Compare
Today's Range
$4.19
Now: $4.25
$4.33
50-Day Range
$2.99
MA: $3.60
$4.62
52-Week Range
$1.12
Now: $4.25
$6.47
Volume115,360 shs
Average Volume14.35 million shs
Market Capitalization$2.85 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.9
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The company's Pharmaceutical segment offers Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, a selective androgen receptor modulator for benign prostatic hyperplasia, and other urologic and metabolic conditions; and OPK88003, a once or twice weekly oxyntomodulin that is in Phase II trials for type 2 diabetes and obesity. It is also developing hGH-CTP, a once-weekly human growth hormone injection in Phase III clinical trial in partnership with Pfizer, Inc.; VARUBI for chemotherapy-induced nausea and vomiting; and Factor VIIa drug for hemophilia. In addition, this segment develops and produces specialty active pharmaceutical ingredients; and discovers drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, it develops, manufactures, markets, and sells pharmaceutical, nutraceutical, and veterinary products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro- intestinal products, hormones, and others. Additionally, the company operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. OPKO Health, Inc. was incorporated in 1991 and is headquartered in Miami, Florida.
Read More
Opko Health logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.38 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:OPK
CUSIP68375N10
Phone305-575-4100
Employees6,096

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$901.90 million
Book Value$2.43 per share

Profitability

Net Income$-314,920,000.00

Miscellaneous

Market Cap$2.85 billion
Next Earnings Date10/29/2020 (Confirmed)
OptionableOptionable
$4.25
+0.07 (+1.67 %)
(As of 10/22/2020 11:03 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OPK News and Ratings via Email

Sign-up to receive the latest news and ratings for OPK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Opko Health (NASDAQ:OPK) Frequently Asked Questions

How has Opko Health's stock been impacted by COVID-19?

Opko Health's stock was trading at $1.69 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, OPK stock has increased by 151.5% and is now trading at $4.25.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Opko Health?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opko Health in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Opko Health
.

When is Opko Health's next earnings date?

Opko Health is scheduled to release its next quarterly earnings announcement on Thursday, October 29th 2020.
View our earnings forecast for Opko Health
.

How can I listen to Opko Health's earnings call?

Opko Health will be holding an earnings conference call on Thursday, October 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Opko Health's earnings last quarter?

Opko Health Inc. (NASDAQ:OPK) announced its earnings results on Thursday, July, 30th. The biotechnology company reported $0.05 EPS for the quarter, beating the consensus estimate of ($0.07) by $0.12. The biotechnology company earned $301.20 million during the quarter, compared to the consensus estimate of $234.57 million. Opko Health had a negative net margin of 20.69% and a negative return on equity of 7.96%.
View Opko Health's earnings history
.

What price target have analysts set for OPK?

3 analysts have issued 12 month target prices for Opko Health's stock. Their forecasts range from $2.50 to $10.00. On average, they expect Opko Health's share price to reach $5.50 in the next year. This suggests a possible upside of 29.4% from the stock's current price.
View analysts' price targets for Opko Health
.

Who are some of Opko Health's key competitors?

What other stocks do shareholders of Opko Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Opko Health investors own include TherapeuticsMD (TXMD), Micron Technology (MU), NVIDIA (NVDA), bluebird bio (BLUE), Gilead Sciences (GILD), Pfizer (PFE), Inovio Pharmaceuticals (INO), Novavax (NVAX), Advanced Micro Devices (AMD) and AT&T (T).

Who are Opko Health's key executives?

Opko Health's management team includes the following people:
  • Dr. Phillip Frost, Chairman & CEO (Age 83)
  • Dr. Jane H. Hsiao M.B.A., Ph.D., MBA, Vice Chairman & CTO (Age 72)
  • Mr. Adam E. Logal, Sr. VP, CFO, Chief Accounting Officer & Treasurer (Age 41)
  • Mr. Steven D. Rubin, Exec. VP of Admin. & Director (Age 59)
  • Ms. Kate Inman, Gen. Counsel & Sec. (Age 46)

What is Opko Health's stock symbol?

Opko Health trades on the NASDAQ under the ticker symbol "OPK."

Who are Opko Health's major shareholders?

Opko Health's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Trellus Management Company LLC (0.39%), Benchmark Financial Wealth Advisors LLC (0.01%), Pacer Advisors Inc. (0.01%), Nisa Investment Advisors LLC (0.00%) and Heron Financial Group LLC (0.00%). Company insiders that own Opko Health stock include Adam Logal, Anthony J Japour, Jane Ph D Hsiao, John A Paganelli, Phillip Md Et Al Frost, Richard C Pfenniger Jr, Robert Scott Fishel and Steven D Rubin.
View institutional ownership trends for Opko Health
.

Which major investors are buying Opko Health stock?

OPK stock was acquired by a variety of institutional investors in the last quarter, including Pacer Advisors Inc., Trellus Management Company LLC, Benchmark Financial Wealth Advisors LLC, Nisa Investment Advisors LLC, and Heron Financial Group LLC. Company insiders that have bought Opko Health stock in the last two years include Adam Logal, Anthony J Japour, Jane Ph D Hsiao, John A Paganelli, Phillip Md Et Al Frost, Richard C Pfenniger Jr, Robert Scott Fishel, and Steven D Rubin.
View insider buying and selling activity for Opko Health
.

How do I buy shares of Opko Health?

Shares of OPK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Opko Health's stock price today?

One share of OPK stock can currently be purchased for approximately $4.25.

How big of a company is Opko Health?

Opko Health has a market capitalization of $2.85 billion and generates $901.90 million in revenue each year. The biotechnology company earns $-314,920,000.00 in net income (profit) each year or ($0.41) on an earnings per share basis. Opko Health employs 6,096 workers across the globe.

What is Opko Health's official website?

The official website for Opko Health is www.opko.com.

How can I contact Opko Health?

Opko Health's mailing address is 4400 BISCAYNE BLVD., MIAMI FL, 33137. The biotechnology company can be reached via phone at 305-575-4100 or via email at [email protected]

This page was last updated on 10/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.